Proxi Biotech
Proxi Biotech is developing novel toxoid-based active immunotherapies that train a patient's own immune system to prevent recurrent bacterial infections, reducing dependence on antibiotics. The company's patent-pending platform targets high-priority unmet needs, including recurrent Clostridium difficile infection and recurrent urinary tract infections, with candidates advancing through preclinical proof-of-concept toward early clinical phases.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Raised to date
€1.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Est. $1.4Macross 1 round
€1.3M · Grant
Announced Sep 2026 · from article date
Disclosed cumulative: $1.4M
Founders
Founder details are not available yet.
Product
Problem
Antimicrobial resistance (AMR) is one of the world's most pressing medical problems, with 1.27 million deaths annually and a projected 2050 death toll exceeding cancer. The overuse and misuse of antibiotics—the current standard of care for bacterial infections—is the root cause of this crisis, leaving patients vulnerable to recurrent infections that are increasingly difficult to treat.
Solution
Proxi Biotech is developing novel, safe, and highly immunogenic toxoid-based active immunotherapies that train the patient's own immune system to fight off bacterial re-infections. By leveraging a proprietary and patent-pending technology platform, the company aims to reduce dependence on antibiotics and provide a preventive approach to managing recurrent infections. The pipeline focuses on high-priority unmet needs, including recurrent Clostridium difficile infection and recurrent urinary tract infection, with the goal of lowering the clinical and economic burden of AMR on healthcare systems. The company advances therapeutic candidates through preclinical proof-of-concept in relevant animal models and into early clinical phases.
Target Audience
Primary customers are healthcare systems, hospitals, and public health organizations seeking preventive solutions for patients at high risk of recurrent bacterial infections, particularly those caused by drug-resistant pathogens.
Features
- Proprietary toxoid-based platform designed to elicit strong immune responses against bacterial toxins
- Patent-pending technology aimed at generating safe, highly immunogenic vaccine candidates
- Pipeline targeting recurrent Clostridium difficile infection, a leading cause of hospital-acquired infections
- Pipeline targeting recurrent urinary tract infections, a common condition with high recurrence rates
- Active immunotherapy approach intended to provide long-lasting protection versus passive antibody treatments
- Versatile toxoid antigen technology developed to create and advance novel immunotherapies against high-priority diseases